# Immuneel Therapeutics Private

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immuneel-therapeutics-private

- Industry: Biotechnology
- Headquarters: Bangalore, India
- Website: www.immuneel.com
- Total disclosed funding: $26M
- Latest round: Series B (Jun 8, 2026)
- Investors on record: 7

## About

Based in India and founded in 2018, Immuneel Therapeutics Private Limited, operates as a biotech company, providing cell therapy and personalized immunotherapy for cancer patients. The company was founded by Biocon founder and chairperson Kiran Mazumdar-Shaw, Dr. Siddhartha Mukherjee, U.S. oncologist and author of the Pulitzer Prize-winning novel, and Kush Parmar. 

Immuneel Therapeutics offers access to Chimeric Antigen Receptor T cell therapy (CAR-T), name named IMAGINE, and other cellular immunotherapies for the management and treatment of cancers. Immuneel’s IMAGINE trial for CD19 CAR-T (IMN-003A) for B cell malignancies (Leukemia & Lymphoma) is ongoing in India. Immuneel has exclusive rights to ARI-0001/IMN-003A (a CD-19 CAR-T cell therapy) from Hospital Clínic de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer in Spain to develop, manufacture and commercialize in India via technology transfer.  

In June 2026, Immuneel Therapeutics Private Limited raised INR 1 billion in series B funding co-led by Singularity AMC and Rainmatter, with participation from Eight Roads Ventures and F-Prime Capital.

The company will use the June 2026 funding to expand GMP manufacturing, strengthen its cell and gene therapy pipeline, and broaden its presence in Asia Pacific and the Middle East.

## Funding rounds

- Series B, Jun 8, 2026, $10M — Eight Roads Ventures, F-Prime Capital, Singularity AMC, Rainmatter
- Series A, Apr 11, 2022, $14M — True North, Khosla Ventures, F-Prime Capital, Apollo Hospitals Enterprise Ltd., Eight Roads Ventures
- Seed, Jan 1, 2020, $1.4M — F-Prime Capital, Eight Roads Ventures

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Seed, Series A, Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Seed, Series A, Series B
- True North (https://capitalatlas.ai/funds/true-north) — Series A
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A
- Apollo Hospitals Enterprise Ltd. — Series A
- Singularity AMC (https://capitalatlas.ai/funds/singularity-amc) — Series B
- Rainmatter (https://capitalatlas.ai/funds/rainmatter) — Series B